Company Overview

PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics intended to improve delivery and uptake into target tissues, particularly skeletal muscle and the central nervous system. The company operates within the biotechnology and rare disease sectors, with a primary emphasis on neuromuscular and neurological disorders. PepGen’s core technology platform combines engineered cell-penetrating peptides with oligonucleotides to enhance intracellular delivery, an area that has historically limited the effectiveness of many RNA-based therapies.

The company’s principal revenue and value drivers are its therapeutic development programs, including candidates targeting Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). PepGen’s strategic positioning is centered on its proprietary enhanced delivery peptide (EDP) platform, which the company states is designed to improve tissue penetration and therapeutic potency relative to conventional oligonucleotide approaches. PepGen was founded in 2018 by researchers associated with the University of Oxford ecosystem and subsequently expanded operations into the United States. The company became publicly traded on Nasdaq under the ticker PEPG in 2022.

Business Operations

PepGen’s operations are primarily organized around research and development activities tied to its therapeutic pipeline and proprietary delivery technologies. Its lead programs include PGN-EDO51 for Duchenne muscular dystrophy amenable to exon 51 skipping and PGN-EDODM1 for myotonic dystrophy type 1. The company generates no material commercial product revenue as of publicly available filings and instead finances operations through equity offerings, cash reserves, and strategic capital raises typical of clinical-stage biotechnology companies.

The company maintains operations in both the United States and the United Kingdom, with research, clinical development, and corporate functions distributed across these markets. PepGen’s principal controlled assets include its proprietary EDP platform and associated intellectual property portfolio related to peptide-mediated oligonucleotide delivery. Public disclosures indicate collaborations with academic researchers and clinical trial institutions, though no large-scale commercial joint venture or revenue-sharing partnership comparable to major pharmaceutical alliances has been prominently disclosed in SEC filings as of available public reporting.

Strategic Position & Investments

PepGen’s strategic direction is focused on advancing its neuromuscular pipeline through clinical development while validating the broader applicability of its delivery platform across additional RNA-targeted therapies. The company has invested heavily in research and clinical infrastructure, with expenditures concentrated on preclinical studies, manufacturing scale-up, regulatory activities, and human clinical trials. Management has consistently emphasized expanding the potential use of its delivery technology beyond DMD into additional rare neuromuscular and neurologic diseases.

The company’s investment profile remains centered on internal platform development rather than large acquisition activity. Publicly available filings do not indicate major transformative acquisitions or extensive subsidiary portfolios. Instead, PepGen’s strategy emphasizes proprietary innovation, intellectual property development, and clinical differentiation in the competitive oligonucleotide therapeutics market. The company operates in a rapidly evolving sector that includes exon-skipping therapies, RNA modulation technologies, and advanced peptide-based drug delivery systems.

Geographic Footprint

PepGen maintains a transatlantic operating presence with headquarters in Boston, Massachusetts, and additional operational and research activities in Oxford, United Kingdom. Its clinical and development activities primarily target regulatory pathways and healthcare markets in North America and Europe, where rare disease drug development incentives and specialist treatment centers are concentrated.

The company’s operational influence is currently strongest in the United States and United Kingdom, although clinical trial activities may involve international study sites depending on patient recruitment requirements. PepGen’s investor base and public market presence are tied primarily to U.S. capital markets through its Nasdaq listing, while its scientific origins and research relationships maintain strong links to the U.K. biotechnology and academic ecosystem.

Leadership & Governance

PepGen’s leadership team combines biotechnology, pharmaceutical development, and scientific research experience. The company’s governance structure reflects a typical publicly traded biotechnology model, with executive management overseeing clinical development, finance, scientific strategy, and operational execution. Public communications and SEC disclosures emphasize a strategy centered on scientific rigor, platform validation, and disciplined advancement of clinical-stage assets.

Key executives include:

• James McArthur, Ph.D. – President and Chief Executive Officer
• Rowel Ian P. Bernales, M.D., MBA – Chief Medical Officer
• Brett P. Monia, Ph.D. – Chief Scientific Officer
• Patrick A. Baeuerle, Ph.D. – Chair of the Board of Directors
• Anastasia K. Makarova – Chief Business Officer
• Jon Evans – Chief Financial Officer

Leadership has consistently communicated a focus on advancing differentiated oligonucleotide therapies through improved delivery efficiency, with corporate strategy emphasizing clinical execution, platform scalability, and long-term expansion into additional rare disease indications.